HROW
HROW
NASDAQ · Pharmaceuticals

Harrow Inc

$43.87
+1.09 (+2.55%)
Financial Highlights (FY 2026)
Revenue
279.97M
Net Income
-5,283,777
Gross Margin
75.0%
Profit Margin
-1.9%
Rev Growth
+45.4%
D/E Ratio
4.64
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 279.97M 192.56M 753.50M 775.29M
Gross Profit 210.12M 144.52M 481.22M 495.14M
Operating Income 23.41M 14.49M 178.06M 162.96M
Net Income -5,283,777 -3,270,788 117.60M 129.68M
Gross Margin 75.0% 75.0% 63.9% 63.9%
Operating Margin 8.4% 7.5% 23.6% 21.0%
Profit Margin -1.9% -1.8% 15.6% 16.7%
Rev Growth +45.4% +45.4% +23.8% +22.8%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 657.25M 657.25M 692.61M 691.25M
Total Equity 141.75M 141.75M 1.12B 1.10B
D/E Ratio 4.64 4.64 0.62 0.63
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA 25.38M 16.58M 185.25M 214.55M
Free Cash Flow 80.89M 86.69M